Browse the evidence

Microneedle (MN)-based technologies provide a painless drug delivery approach that targets adipose tissue directly, minimizing systemic exposure and reducing the required dosage.

Practitioners may consider MNs as a viable alternative for delivering anti-obesity medications effectively.

The goal of management in T2D patients with significant fibrosis is to slow the progression of liver disease and reduce associated clinical events.

Clinicians should aim to adapt therapies to manage liver disease progression in diabetic patients.

Significant weight loss can lead to aesthetic challenges such as skin laxity.

Practitioners should be aware of potential aesthetic issues in patients after significant weight loss.

Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass.

Monitor for gastrointestinal side effects and potential muscle and bone mass loss in patients using GLP-1 receptor agonists.

There are trivial hypertrophic effects between proximal, mid-belly, and distal muscle sites.

Trivial differences in hypertrophy suggest that exercise selection may not need to prioritize specific muscle lengths.

GLP-1 receptor agonists may modify aortic disorders through anti-inflammatory, antioxidant, and antiatherogenic properties.

GLP-1 RAs could be considered for patients with aortic disorders due to their beneficial properties.

Early identification of physical frailty in the liver transplantation clinical pathway is essential for targeted interventions.

Clinicians should implement screening tools for frailty in liver transplant candidates to tailor interventions.

All active treatments, including Dapagliflozin 10 mg, Survodutide, Tirzepatide, and higher-dose Semaglutide, improved fibrosis versus placebo.

Practitioners can consider these anti-diabetic agents as effective options for improving liver fibrosis in patients with MASH.

Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement.

Practitioners should consider the dosage of anti-diabetic agents when aiming for MASH resolution.

GLP-1 agonists influence various obesity-related processes including food intake regulation, insulin resistance, and inflammation.

Understanding these mechanisms can help practitioners tailor obesity treatments more effectively.

Metabolic dysfunction associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide.

Healthcare providers should recognize MASH as a significant health concern.

MASLD presents extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, and chronic kidney disease.

Clinicians should consider the broader health implications of MASLD beyond liver health.

Obesity, sarcopenia, and heart failure with preserved ejection fraction (HFpEF) are interconnected through the adipokine axis.

Understanding the link between these conditions can guide treatment strategies.

Fecal transplant may have a preventive role in diabetes progression.

Consider the potential of fecal transplants in diabetes prevention strategies.

Patients who have undergone significant weight loss are at increased risk of thromboembolic events, particularly after body contouring procedures.

Practitioners should monitor thromboembolic risk in post-weight-loss patients undergoing surgery.

MPDA@TZP increased the retention time of TZP in the iWAT of mice and had a more dramatic effect on weight loss and improvement in plasma lipid profiles compared to TZP alone in DIO mice.

Encapsulating tirzepatide may enhance its effectiveness for weight loss in specific adipose tissues.

Mitochondrial dysfunction plays a pivotal role in the onset and progression of diabetes.

Understanding mitochondrial dysfunction can guide therapeutic strategies for diabetes management.

Innovative therapeutic strategies are needed to address mitochondrial dysfunction in diabetes.

Practitioners should consider new therapies targeting mitochondrial function in diabetes care.

Grip strength declined by 38% following semaglutide treatment.

Monitoring grip strength may be important in patients receiving GLP-1RA therapy to assess muscle function.

Key therapeutic areas include innovative approaches for monogenic disorders, incretin mimetics, dual receptor agonists, microbiome analysis, and improved behavioural interventions.

Practitioners should consider these therapeutic areas for advancing treatment options.

The etiology of obesity is multifactorial, and long-term weight maintenance remains challenging.

Interventions for obesity must consider the multifactorial nature of the condition.

Adverse effects of dual agonists are largely gastrointestinal and manageable.

Healthcare providers should inform patients about the manageable gastrointestinal side effects of dual agonists.

All exercise groups (WB-EMS, Pilates, Yoga) significantly reduced muscle mass during diet-induced weight loss compared to the control group.

Incorporating exercise like WB-EMS, Pilates, or Yoga can help mitigate muscle loss during weight loss diets.

The activation of GLP-1R by semaglutide or THDBH120 improved lipid metabolism.

GLP-1R activation could be targeted for improving lipid metabolism in obese patients.